HK1247558A1 - 塞内可瑞伟洛克(cenicriviroc)用於治疗纤维化 - Google Patents

塞内可瑞伟洛克(cenicriviroc)用於治疗纤维化 Download PDF

Info

Publication number
HK1247558A1
HK1247558A1 HK18106984.5A HK18106984A HK1247558A1 HK 1247558 A1 HK1247558 A1 HK 1247558A1 HK 18106984 A HK18106984 A HK 18106984A HK 1247558 A1 HK1247558 A1 HK 1247558A1
Authority
HK
Hong Kong
Prior art keywords
cenicriviroc
fibrosis
treatment
peritonitis
solvate
Prior art date
Application number
HK18106984.5A
Other languages
English (en)
Chinese (zh)
Inventor
Eric Lefebvre
Original Assignee
Tobira Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tobira Therapeutics, Inc. filed Critical Tobira Therapeutics, Inc.
Publication of HK1247558A1 publication Critical patent/HK1247558A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK18106984.5A 2015-02-10 2015-09-22 塞内可瑞伟洛克(cenicriviroc)用於治疗纤维化 HK1247558A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562114304P 2015-02-10 2015-02-10
US62/114,304 2015-02-10
PCT/US2015/051467 WO2016130179A1 (en) 2015-02-10 2015-09-22 Cenicriviroc for the treatment of fibrosis

Publications (1)

Publication Number Publication Date
HK1247558A1 true HK1247558A1 (zh) 2018-09-28

Family

ID=56614560

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18106984.5A HK1247558A1 (zh) 2015-02-10 2015-09-22 塞内可瑞伟洛克(cenicriviroc)用於治疗纤维化

Country Status (15)

Country Link
US (3) US20180110754A1 (enExample)
EP (1) EP3256124B1 (enExample)
JP (2) JP6676660B2 (enExample)
KR (1) KR20170113596A (enExample)
CN (1) CN107405403B (enExample)
AU (1) AU2015382376B2 (enExample)
BR (1) BR112017016388A2 (enExample)
CA (1) CA2975445A1 (enExample)
ES (1) ES2864767T3 (enExample)
HK (1) HK1247558A1 (enExample)
IL (1) IL253617A0 (enExample)
MX (1) MX2017010277A (enExample)
RU (1) RU2722641C2 (enExample)
SG (1) SG11201706028RA (enExample)
WO (1) WO2016130179A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7371772B2 (en) 2001-08-08 2008-05-13 Takeda Pharmaceutical Company Limited Bicyclic compound, production and use thereof
SG11201704837VA (en) 2014-12-23 2017-07-28 Tobira Therapeutics Inc Process of making cenicriviroc and related analogs
BR112018076449A2 (pt) 2016-06-21 2019-04-09 Tobira Therapeutics, Inc. cenicriviroc purificado e intermediários purificados para fazer cenicriviroc
WO2022235440A1 (en) * 2021-04-21 2022-11-10 The United States Government As Represented By The Department Of Veterans Affairs Method for treating traumatic brain injury, spinal cord injury, or stroke using small molecule inhibitors of ccr2
CN116270633A (zh) * 2023-03-03 2023-06-23 神经肌肉骨骼再生医学中心有限公司 马拉韦罗在制备治疗肌肉退行性疾病的药物中的用途
CN119954974B (zh) * 2025-04-09 2025-07-22 四川康德赛医疗科技有限公司 一种工程化巨噬细胞，其制备方法及抗纤维化的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2249027A (en) * 1990-10-23 1992-04-29 Fujisawa Pharmaceutical Co Use of macrolide compounds for hepatic failure
US7371772B2 (en) 2001-08-08 2008-05-13 Takeda Pharmaceutical Company Limited Bicyclic compound, production and use thereof
EP1825866A4 (en) 2004-12-03 2008-03-12 Takeda Pharmaceutical SOLID PREPARATION
US8148356B2 (en) * 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
DK2723360T3 (en) * 2011-06-27 2017-08-28 Univ Pierre Et Marie Curie Paris 6 CCR2 antagonist peptides
JP6263814B2 (ja) * 2013-03-05 2018-01-24 国立大学法人 岡山大学 細胞死抑制剤及び新規化合物
KR20160013068A (ko) * 2013-05-15 2016-02-03 토비라 쎄라퓨틱스, 인크. 세니크리비록 조성물 및 이들을 만들고 이용하는 방법
KR101669124B1 (ko) * 2013-07-11 2016-10-25 서울대학교병원 인간 배아줄기세포에서 유래된 중간엽 줄기세포를 유효성분으로 함유하는 간섬유화 또는 간경화 예방 및 치료용 조성물

Also Published As

Publication number Publication date
EP3256124A1 (en) 2017-12-20
RU2017130289A3 (enExample) 2019-04-22
AU2015382376A1 (en) 2017-08-17
MX2017010277A (es) 2017-12-07
RU2017130289A (ru) 2019-03-12
KR20170113596A (ko) 2017-10-12
SG11201706028RA (en) 2017-08-30
ES2864767T3 (es) 2021-10-14
AU2015382376B2 (en) 2021-07-01
US20200360347A1 (en) 2020-11-19
WO2016130179A1 (en) 2016-08-18
US20190343806A1 (en) 2019-11-14
CN107405403B (zh) 2021-04-20
JP2018505218A (ja) 2018-02-22
CN107405403A (zh) 2017-11-28
JP6676660B2 (ja) 2020-04-08
CA2975445A1 (en) 2016-08-18
RU2722641C2 (ru) 2020-06-02
IL253617A0 (en) 2017-09-28
JP2020111586A (ja) 2020-07-27
BR112017016388A2 (pt) 2018-03-27
US20180110754A1 (en) 2018-04-26
EP3256124B1 (en) 2020-12-23
EP3256124A4 (en) 2018-09-26

Similar Documents

Publication Publication Date Title
MX2016012262A (es) Cenicriviroc para el tratamiento de fibrosis.
IL256085B (en) A converted derivative of huanic acid, a pharmaceutical preparation containing it and the converted derivative for use in treatment
CA2956871C (en) Compounds active towards bromodomains
WO2017087608A8 (en) Modulators of ror-gamma
WO2015077503A8 (en) Autotaxin inhibitor compounds
EP3484504A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT OF DISEASE
HK1247201A1 (zh) 2-(5-(3-氟苯基)-3-羟基吡啶甲醯胺)乙酸的固体形式、其组合物及用途
EP3268007A4 (en) Compositions and therapeutic methods for the treatment of complement-associated diseases
EP3606570B8 (en) Collagen peptide-based medicament compositions for use in the treatment of ocular diseases, disorders or wounds
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
MX2017010277A (es) Cenicriviroc para el tratamiento de la fibrosis.
WO2015106215A3 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
WO2014121137A3 (en) Compositions and methods for the treatment of neurodegenerative and other diseases
WO2016080796A3 (ko) 세스퀴테르펜 화합물을 포함하는, stat3 매개 질환의 예방 또는 치료용 약학적 조성물 및 이의 용도
EP3119387A4 (en) Compositions for the treatment of dermatological diseases and disorders
EP3291818A4 (en) Compositions and methods for delivering therapeutic agents into the colon
IL280389A (en) Bile acid receptor modulators conjugated to G.1 protein and methods of using them
EP3579825A4 (en) SULPHAMOYLTHIOPHENAMIDE DERIVATIVES AND USES THEREOF AS MEDICINES FOR TREATMENT OF LIVER FIBROSIS
EP3322435A4 (en) Pharmaceutical compositions useful for the treatment of tissue injury
WO2016144706A3 (en) Autotaxin inhibitor compounds and uses thereof
WO2016144704A3 (en) Heterocyclic autotaxin inhibitor compounds
WO2017210527A8 (en) Autotaxin inhibitors
EP3271326A4 (en) Compositions for the treatment of kidney and/or liver disease
HK40036525A (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
HK40030474A (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases